speaker
Conference Operator
Operator

Greetings and welcome to the Edwards Life Sciences third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Jerrianne Sarte, Senior Vice President, Investor Relations. Thank you. You may begin.

speaker
Jerrianne Sarte
Senior Vice President, Investor Relations

Good afternoon, and thank you for joining us. With me on today's call is our CEO, Bernard Zovighian, and our CFO, Doretta Mistras. Also joining us for the Q&A portion of the call will be Dan Lippis, our global leader of TAVR, and Daveen Chopra, who has global responsibility for TMTT, Surgical, and IHFM. After the close of regular trading, Edwards Life Sciences released third quarter 2026 financial results. During today's call, management will discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions, and projections. These statements speak only as of the date on which they are made, and Edwards does not undertake any obligation to update them after today. The statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Factors that could cause these differences can be found in today's press release and Edwards' other SEC filings, all of which are available on the company's website at edwards.com. Unless otherwise noted, our commentary on sales growth refers to underlying sales growth, which is defined in the financial results press release issued earlier today. Reconciliations between GAAP and non-GAAP numbers mentioned during this call are also included in today's press release. Quarterly and full-year growth rates refer to continuing operations. With that, I'll turn the call over to Bernard for his comments.

speaker
Bernard Zovighian
Chief Executive Officer

Thank you, Jerian, and welcome, everyone. We delivered third-quarter results that exceeded expectations. with both our businesses and regions driving strong broad-based performance. Even more importantly, we achieved meaningful progress on several of our most important clinical regulatory policy and commercial priorities, strengthening our outlook for durable long-term growth. The consistency of our top-tier financial performance is a reflection of our focused strategy as well as our commitment to innovation Speed and agility and the strength of execution by our 17,000 dedicated employees across Edwards. Third quarter sales of $1.72 billion grew 11.2%. This performance was driven by our structural heart portfolio, including continuous strength in TAVR and growing contributions from our portfolio of TMTT therapies with Pascal, Evoque, and Sapien M3. Based on our strong performance this quarter, we are raising our full year sales growth guidance to approximately 11.5% and our adjusted EPS guidance to $2.97 to $3.05, growing 18% at the midpoint versus prior year. As I reflect on 2026 so far, I am proud of what our teams have accomplished and how we are positioning Edwards for the future. We are clear on our strategy focusing on structural heart, a large and growing space with significant and met patient needs. We invest early, taking a long-term view with conviction to create entirely new categories of treatment that push the boundaries of what is possible for underserved patients. And at the same time, we are moving with intention, sharpening how we are operating, embracing science and technology advancements Accelerating decision-making and executing against an important set of priorities. Our focus continues to deliver meaningful progress across the company, underpinned by our foundational patient-focused culture. All of this together sets us apart and is why we are confident in our long-term success. We are pleased to see our strategy deliver particularly impressive progress over the last few months. with five meaningful therapy approvals that offer new options to physicians. In addition, we continue to elevate the clinical evidence standard for structural heart care, including the release of two new practice changing data sets. In TAVR, the SAPIEN platform continues to set the benchmark for valve performance and durability. supported by ongoing innovation and world-class clinical evidence. The PROGRESS trial marks a turning point in our collective understanding and management of moderate AS. Taken all together, the PROGRESS trial results, early TAVR clinical outcomes, and long-term cost effectiveness data, and partner-free seven-year durability data are advancing the understanding of aortic stenosis as a disease and reinforcing the differentiation of TAVR with the SAPIEN platform as a compelling treatment strategy for CVAS. As a result, this changes how the clinical community looks at the disease, how to evaluate, who to treat, when to treat and ultimately this underscores the value of proactive disease management with the SAPIEN platform. In addition, The modernization of the NCD represents an important step toward expanded access to TAVR through timely, high-quality care for all AS patients. In TMTT, our years of pioneering development and strategic investment have resulted in a portfolio of therapies allowing our teams A unique opportunity to collaborate with physicians to personalize care for the clinically diverse patients suffering from mitral and tricuspid diseases. With the recent U.S. approvals of PASCAL for tricuspid patients and next-generation capture clarity for mitral patients, we are further strengthening the portfolio of treatment options in surgical, We continue to see strong adoption of our Resilia portfolio of therapies and we continue to introduce new therapies to address unmet patient needs, including Otis for congenital patient and Ecliptis for surgical left atrial appendage occlusion. At the same time, we are applying our proven innovation playbook to new areas of significant unmet need within structural heart, including structural heart failure and aortic regurgitation. creating additional opportunities for long-term growth. When I reflect on all of this, I am proud of our impact. When EDWARDS leads, everyone benefits. Physicians, providers, payers, and most importantly patients who enjoy a restored quality of life and live longer. Now, let's dive a little deeper into the recent presentation at ECT. Physicians presented compelling new evidence on Sapien, Pascal, Evoke, and Sapien M3 that deepens the clinical community's understanding of these therapies and underscores their significant potential to transform care for AS, mitral, and tricuspid patients. The breadth and quality of this evidence reflects the strength of our innovation strategy and our commitment to setting the benchmark for clinical evidence and structural heart disease. Putting all of this in perspective, these advancements represent meaningful multi-year opportunities that we expect to build over time and which underpin our long-term growth target of approximately 10% average annual sales growth alongside leveraged EPS growth. Now, I will provide more detail about the performance of our product groups. TAVR third quarter global sales of $1.2 billion were stronger than expected and increased 8.8% over the prior year. AdWords growth rates were similar in the US and outside of the US. Globally, procedural growth benefited from a heightened focus on TAVR and data supporting proactive disease management of CVRS. Exiting Q3, We saw encouraging signs of procedure growth. After several quarters of modest share gains, we are pleased with how our competitive position supported by our differentiated SAPIEN platform has contributed to year-to-date TAVR performance. Average selling prices were stable globally. At TCT, results from the progress trial were presented and published in the New England Journal of Medicine marking a turning point in the management of moderate AS. The remarkable performance and unparalleled safety of the SAPIEN platform coupled with the superior trial results validate TAVR as a treatment strategy for moderate AS patients with at-risk features. These findings challenge the long-standing assumption Thank you very much. Thank you very much. and unpredictable progression of aortic stenosis and continues to validate the patient benefit of proactive disease management. Also presented at TCT was ACTIVATE, a large real world investigator initiative study of more than 53,000 patients with AS who were identified with an advanced healthcare system using EHR. The study demonstrated that patients with moderate AS outnumber those with severe AS nearly 2 to 1. Additionally, among the patients with moderate AS, approximately 80% had at least one at-risk feature, which was associated with an increased risk of death and hospitalization. The evidence from PROGRESS and ACTIVATE suggests that the in-system and out-of-system moderate opportunity is at least as large as the severe AS opportunity. We will continue to share our perspectives on the moderate patient opportunity as the evidence continues to grow and the clinical community gains experience managing this patient over time. Additionally, new long-term economic data from the early TAVR trial reinforced the value of proactive disease management in patients with asymptomatic severe aortic stenosis. Edward Stiver delivered exceptional economic value compared with clinical surveillance and remained highly cost-effective even after accounting for potential future valvular re-intervention. Notably, this result was achieved in a highly controlled trial setting where patients benefited from optimal care and treatment with a median time to intervention of just 32 days compared with approximately 157 days observed in real-world practice. Taken together, the practice-changing early TAVR and progress studies deepen our understanding of aortic stenosis and continue to validate the patient benefit of proactive disease management. This evidence is now clear that intervening before the disease progresses avoids significant health decline and serious cardiovascular events such as heart failure-related hospitalization and death. Let me now turn to some commentary on U.S. TAVR. In Q3, procedure growth continued to benefit from a heightened focus on TAVR therapy as the clinical community further incorporates into practice the meaningful evidence supporting proactive disease management. Edwards' competitive position in the U.S. was stable sequentially and increased modestly year over year, enabled by strong adoption of our differentiated CPN3 Ultra Resilia. During the quarter, CMS released the final updated NCD for TAVR. We are pleased that the updated policy represents an important step toward improving and expanding timely, high-quality access to care while reinforcing the value of a multidisciplinary heart team. We believe there are four important elements within the NCD. First, the policy will enable greater flexibility for the heart team at every step of the patient journey, from evaluation to treatment. Second, it will support appropriate site expansion over time for updated hospital procedure volume requirements. Third, the NCD will expand coverage to asymptomatic patients. And finally, The policy provides a pathway to coverage for Medicare administrative contractors, or MACs, to address reasonable and necessary coverage when future TAVR indications are approved. Taken together, these changes establish a strong foundation that will expand timely, high-quality access to care, support the continued evolution of TAVR, and ensure that more patients with aortic stenosis will benefit from treatment for many years to come. Outside of the US, we continue to see strong adoption of our sapient technology. In Europe, updated ESC and EAX guidelines are helping shape clinical discussion around earlier intervention and proactive disease management, further reinforcing the role of TAVR across a broader patient population. Edward's competitive position increased modestly year over year in Europe. In Japan, we continue to be encouraged by the growth and the continued adoption of Sapien Free Ultra Resilia. Also in Japan, we secured new and dedicated reimbursement for Sapien Free Ultra Resilia, which recognizes the value of our innovation and helped contribute to Japan's strong performance in the quarter. In summary, we are pleased with our TAVR performance in the quarter, which was a reflection of procedure growth and competitive position. Given our better than expected third quarter performance, we are raising our full year TAVR guidance to 9 to 9.5%. In the fourth quarter and going forward, we are assuming that growth will be mainly driven by continued increases in procedure volume and less by ShareGains. Putting it all together, there is robust evidence and emerging indication validating the patient benefits of proactive disease management for AS and with the opportunity that comes from the modernized NCD in the US, we have reinforced confidence in the durable mid to high single digit growth of our SAPIEN platform over the long term. Now, let me turn to TNTT. Our differentiated portfolio of mitral and tracheal speed repair and replacement therapies drove third-quarter sales of $207 million, an increase of 45.6% year-over-year. Globally, mitral and tracheal speed procedure volumes continue to grow in the double digits. The value of our TMTC portfolio is evident as our mitral and tricuspid therapies advance along their adoption curves, allowing our teams to collaborate with physicians to personalize care for each patient's unique needs. With the recent approval of Pascal Precision for tricuspid regurgitation, our full portfolio of repair and replacement technologies for the mitral and tricuspid valves is now available in the U.S. as it has been for physicians in Europe. Growth was strong globally, and as the U.S. scales, it is becoming a more significant driver. New clinical data across the entire portfolio continues to strengthen the growing body of meaningful evidence supporting long-term adoption of our TMTT therapies. This was evident at TCT, where seven clinical presentations feature compelling new data from across the portfolio. Turning to an update on each of our TMTT therapy areas. Starting with Pascal. Adoption continues to strengthen, supported by the differentiated design and clinical outcome of a platform in our portfolio approach. The class two-tier pivotal trial presented at TCT met its six-month primary endpoints. demonstrating the superiority of the PASCAL system plus optimal medical therapy compared with OMT alone in patients with severe or greater TR. This was driven by significant improvements in health status for those receiving PASCAL. During the quarter, PASCAL ACE with capture clarity received US approval for use in DMR tier procedures. and a major rollout of the technologies underway. Pascal ACE, with CaptureClarity, is the first FDA-approved tear device to include novel indicators that provide confirmation of a challenging step of leaflet grasping. In October, Pascal Precision for tricuspid regurgitation received approval in the U.S., expanding access to this important therapy for patients. Early clinician feedback is very positive on both pascal capture clarity and pascal tricuspid. Clinicians value the simplification of device placement with the new feature of capture clarity. With pascal tricuspid, physicians are recognizing that unique features including device integration are particularly beneficial for patients with complex tricuspid anatomy. Our focus on continued innovation with PASCAL represent a positive step forward for patients in need for mitral and tricuspid repair. Moving to tricuspid replacement, EVOC delivered another strong quarter of growth. As physicians gain experience with EVOC, they are more consistently achieving mild or less residual TR, a result that is increasingly linked to better outcome for patients. We also recently received US approval in CMARC for EVOC for transjugular access, enabling patients with complex femoral access to benefit from the EVOG procedure. In addition, a TCT result from EVOG patients in the TBT registry with CMS linkage demonstrated that the real-world clinical outcomes of patients with more complex disease replicate those observed in the TRICEN2 clinical trial. In more than 1,100 patients who were followed through one year, EVOC delivers sustained elimination of TR and quality of life improvements, excellent valve durability, and high rate of procedural success. Building upon the body of clinical evidence supporting tricuspid intervention, the EDWAR-supported TRIC-EHF study demonstrated statistically significant reduction in the combination endpoint of heart failure, hospitalization, and mortality, for tricuspid intervention compared with optimal medical therapy at one year. Together, the meaningful evidence focused on tricuspid intervention advances clinical practice by highlighting the importance of interventional therapy for TR. Moving to CPNM3. We continue to see strong demand for patients who are not suitable for mitral tear and we are encouraged by the excellent early clinical outcomes delivered by the therapy. Two-year results from N-Circle presented recently at TCT reinforced the durability of CPNM3, including sustained reduction of MR, functional improvement, and quality of life benefits. In addition, we introduced CPNM3 with Resilia in Europe this quarter. Resilia tissue is a key element of Edwards' innovation, extending durability for patients who receive our valves, and we plan to incorporate this advanced tissue treatment across all TMTT valve replacement therapies. In summary, based on our strong performance, we now expect full-year TMTT cells to be between 780 and 790 million dollars. Our full portfolio of innovative technologies is now available to patients across the U.S. and Europe, and we are just beginning to realize the opportunity ahead. Together, Pascal, Evoque, and Sapien M3 provide layers of durable growth that support our path to $2 billion in TMTT revenue in 2030. In surgical, Third quarter global sales of $264 million increased 3% over the prior year, driven by continued adoption of Resilia portfolio of surgical therapies. Our expectation of full year mid single digit sales growth for surgical remains unchanged. We are expanding the surgical portfolio with innovative technologies that address additional in structural heart surgery. During the quarter, Otis, became the first FDA-approved surgical pulmonorevalve designed specifically for pediatric anatomy with the ability to expand as a child grows, potentially reducing the need for repeat open-heart surgeries. We are also advancing a major rollout of ECLIPTIS, our surgical left atrial appendage technology in the U.S., prioritizing exceptional outcomes for patients through physician training and procedural excellence. In summary, we are pleased with the continued strength of our surgical portfolio and the progress we are making to reach new patients best treated surgically. With that, we'll pass it over to Dorreta to cover the detail of our financial results.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Q3EW 2026

-

-

Investor presentation